VOMARIS PATENT ESTATE GROWS TO SIX ISSUED U.S. PATENTS AND THREE GRANTED INTERNATIONAL PATENTS WITH U.S. PAT. NO. 8,224,439
Vomaris Innovations, Inc, a leading regenerative medicine company focusing on wound care with bioelectric technology, has been granted another patent (U.S. Pat. No. 8,224,439) related to its bioelectric technology surrounding the use of devices that rely upon reducing and oxidizing agents to treat biologic tissue and promote healing. “Our growing and valuable patent estate is indicative of the powerful momentum behind our leading bioelectric technology,” said Michael P. Nagel, Vomaris President and CEO. “Procellera® is transforming the way wounds are managed,” he added, “which will create meaningful cost savings while enhancing the quality of patient care worldwide.” Procellera is the first totally self-contained, conformable, cut-to-fit, electrically active wound dressing in the world. The technology is extremely versatile and scalable and spans multiple healthcare industries.